Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
ZNTL

Zentalis Pharmaceuticals (ZNTL) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $2.64 +5.2% on the day +45.9% over 12 months 52-week range $1.28 – $6.61

Share price and insider trades

ZNTL closeInsider buyInsider sale
02468NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $1,401 on 2026-02-03 · Vincent VultaggioSold $6,477 on 2026-02-02 · Vincent VultaggioSold $11,001 on 2026-02-09 · Ingmar Bruns, Julia Marie Eastland, Vincent VultaggioSold $16,683 on 2026-02-10 · Vincent VultaggioSold $99,093 on 2026-02-06 · Ingmar Bruns, Julia Marie Eastland, Vincent VultaggioBought $7,751,968 on 2025-12-31 · William Thurman WaltersSold $9,975,000 on 2025-12-15 · David E. GoelBought $15,172,500 on 2026-08-14 · William Thurman Walters
Bought, 12 months$22.9M
Sold, 12 months$10.1M
Insiders buying1
Insiders selling4

Zentalis Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $22.9M and 4 sold $10.1M of ZNTL stock on the open market.

ZNTL insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $7.8M bought (1 trades)$7.8MQ4 2025: $10.0M sold (1 trades)Q4 2025Q1 2026: $135K sold (9 trades)Q1 2026Q2 2026Q3 2026: $15.2M bought (1 trades)$15.2MQ3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$15.2M1—0
Q2 2026—0—0
Q1 2026—0$135K9
Q4 2025$7.8M1$10.0M1

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$259MBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit+$5.6MOn all tracked purchases +24.3%

Summary

Over the past 12 months, 1 Zentalis Pharmaceuticals, Inc. insider reported open-market purchases totaling $22.9M, while 4 insiders reported sales totaling $10.1M. 5 of 10 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ZNTL stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Aug 19SEC William Thurman Walters10% Owner Buy 4,335,00017,844,973 held (+32%) $3.50 $15.2M -24.6% —
Feb 10SEC Vincent VultaggioPao And Pfo Sell Plan 29,951156,779 held (−16%) $2.43 $73K +8.6% —
Feb 10SEC Julia Marie EastlandCEO, President Sell 7,86680,022 held (−9%) $2.43 $19K +8.6% —
Feb 10SEC Vincent VultaggioPao And Pfo Sell Plan 6,894146,506 held (−4%) $2.42 $17K +9.1% —
Feb 10SEC Vincent VultaggioPao And Pfo Sell Plan 3,379153,400 held (−2%) $2.39 $8K +10.5% —
Feb 10SEC Ingmar BrunsChief Medical Officer Sell 2,96233,667 held (−8%) $2.43 $7K +8.6% —
Feb 10SEC Julia Marie EastlandCEO, President Sell 88979,133 held (−1%) $2.39 $2K +10.5% —
Feb 10SEC Ingmar BrunsChief Medical Officer Sell 33533,332 held (−1%) $2.39 $801 +10.5% —
Feb 4SEC Vincent VultaggioPao And Pfo Sell Plan 2,540187,286 held (−1%) $2.55 $6K +3.5% —
Feb 4SEC Vincent VultaggioPao And Pfo Sell Plan 556186,730 held (−0%) $2.52 $1K +4.8% —
Jan 8SEC William Thurman Walters10% Owner Buy 6,459,97313,509,973 held (+92%) $1.20 $7.8M +120.0% —
Dec 15SEC David E. Goel10% Owner Sell 7,500,0006,459,973 held (−54%) $1.33 $10.0M +98.5% —

Insiders at Zentalis Pharmaceuticals, Inc.

InsiderBoughtSoldLast filingScore
William Thurman Walters10% Owner $22.9M — Aug 19, 2026 —
David E. Goel10% Owner — $10.0M Dec 15, 2025 —
Vincent VultaggioPao And Pfo — $105K Feb 10, 2026 —
Julia Marie EastlandCEO, President — $21K Feb 10, 2026 —
Ingmar BrunsChief Medical Officer — $8K Feb 10, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

ZNTL stock: common questions

Are Zentalis Pharmaceuticals, Inc. insiders buying ZNTL stock?

In the past 12 months, 1 insiders reported open-market purchases of ZNTL worth $22.9M. The latest was 10% Owner William Thurman Walters bought $15.2M of ZNTL at $3.50 — largest purchase by this insider in our records; raises the stake by 32%.

Are Zentalis Pharmaceuticals, Inc. insiders selling ZNTL stock?

4 insiders reported sales worth $10.1M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ZNTL's 52-week range?

Over the past year ZNTL has traded between $1.28 and $6.61. It last closed at $2.64 on Oct 9, 2026.